Fosun Pharma H-Share Repurchase Plan
Analysis based on 6 articles · First reported Jul 20, 2026 · Last updated Sep 07, 2026
The repurchase plan signals management confidence and may support Fosun Pharma's share price. The partial disposal of Gland Pharma provides funding for the buyback and debt repayment, potentially improving balance sheet strength.
Fosun Pharmaceutical Group announced an H-share repurchase plan of up to HK$1 billion, funded by proceeds from the disposal of approximately 6% equity interest in Gland Pharma for around US$294 million. The repurchase aims to respond to market concerns and demonstrate management confidence. Fosun Pharma reported H1 2026 revenue of RMB 20,442 million, up 4.75% year-on-year, and net profit attributable to shareholders of RMB 1,144 million, up 19.09%.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard